What one share of Exagen holds
We are a medical technology company primarily focused on the design, development and commercialization of a next-generation portfolio of innovative testing products under our AVISE® brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Exagen’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.01 |
|---|---|
| Profit | −$0.80 |
| Capex (buildings and equipment) | $0.05 |
| Free cash flow | −$0.32 |
| Cash and investments | $1.02 |
| Debt | $1.06 |
| Book value | $0.50 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $514.88 | −$293.34 | $3.16 | −$150.78 | — | −$1,777 |
| 2019 | $11.29 | −$8.46 | $0.11 | −$2.83 | — | — |
| 2020 | $3.32 | −$1.32 | $0.04 | −$1.15 | — | $3.31 |
| 2021 | $3.02 | −$1.68 | $0.15 | −$1.42 | — | $5.25 |
| 2022 | $2.67 | −$2.77 | $0.25 | −$2.13 | — | $2.57 |
| 2023 | $2.97 | −$1.34 | $0.05 | −$0.86 | — | $1.33 |
| 2024 | $3.06 | −$0.83 | $0.03 | −$0.76 | — | $0.54 |
| 2025 | $3.09 | −$0.93 | $0.03 | −$0.66 | — | $0.76 |
Common questions about Exagen
How much does one share of Exagen earn?
Over the last 12 months, Exagen lost $0.80 for each share on $3.01 of sales.
Does Exagen pay a dividend?
Exagen didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Exagen’s book value per share?
Exagen’s book value is $0.50 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Exagen have?
Each share of Exagen has $1.02 of cash and investments and $1.06 of debt, as of June 30, 2026.
What is Exagen’s free cash flow per share?
−$0.32 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Exagen bought back shares?
Exagen’s share count rose about 34117% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.